This case consult with Drs. Kaiser and Borkar presents a patient with newly diagnosed vision loss. After reviewing the diagnosis, the faculty discuss intravitreal anti-VEGF treatment options including the more durable therapies for neovascular age-related macular degeneration (nAMD). Approaches to selecting an agent and determining dosing intervals are demonstrated over 72 weeks of treatment.